RT Journal Article
SR Electronic
T1 Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.29.20184358
DO 10.1101/2020.08.29.20184358
A1 Zuo, Yu
A1 Warnock, Mark
A1 Harbaugh, Alyssa
A1 Yalavarthi, Srilakshmi
A1 Gockman, Kelsey
A1 Zuo, Melanie
A1 Madison, Jacqueline A.
A1 Knight, Jason S
A1 Kanthi, Yogendra
A1 Lawrence, Daniel A.
YR 2020
UL http://medrxiv.org/content/early/2020/09/21/2020.08.29.20184358.abstract
AB Background Patients with coronavirus disease 19 (COVID-19) are at high risk for thrombotic arterial and venous occlusions. At the same time, bleeding complications have been observed in some patients. Better understanding the balance between coagulation and fibrinolysis will help inform optimal approaches to thrombosis prophylaxis and potential utility of fibrinolytic-targeted therapies.Methods 118 hospitalized COVID-19 patients and 30 healthy controls were included in the study. We measured plasma antigen levels of tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) and performed spontaneous clot lysis assays.Findings We found markedly elevated levels of tPA and PAI-1 among patients hospitalized with COVID-19. Both factors demonstrated a strong correlation with neutrophil counts and markers of neutrophil activation. High levels of tPA and PAI-1 were associated with worse respiratory status. High levels of tPA, in particular, were also strongly correlated with mortality and with a significant enhancement in spontaneous ex vivo clot lysis.Interpretation While both tPA and PAI-1 are elevated among COVID-19 patients, extremely high levels of tPA enhance spontaneous fibrinolysis and are significantly associated with mortality in some patients. These data indicate that fibrinolytic homeostasis in COVID-19 is complex with a subset of patients expressing a balance of factors that may favor fibrinolysis, and suggest that further study of tPA as a potential biomarker is warranted.Funding COVID-19 Cardiovascular Impact Research Ignitor Grant from the Michigan Medicine Frankel Cardiovascular Center, the National Institutes of Health, the A. Alfred Taubman Medical Research Institute, the Rheumatology Research Foundation, the Lupus Research Alliance, the Falk Medical Research Trust, the Burroughs Wellcome Fund, and the JOBST-American Venous Forum.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was supported by a COVID-19 Cardiovascular Impact Research Ignitor Grant from the Michigan Medicine Frankel Cardiovascular Center, the A. Alfred Taubman Medical Research Institute, and the National Institutes of Health (HL055374 to DAL).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study complied with all relevant ethical regulations and was approved by the University of Michigan IRB (HUM00179409).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made available upon publication.